MENU

Insiders have been buying these 3 ASX shares

Once a week I like to look at which ASX shares have been experiencing insider buying and selling.

This is because in theory nobody should know a company and its prospects better than its directors. So when insiders are shown to be buying shares it is often regarded as a bullish indicator and vice versa when they are seen to be selling shares.

Three shares which have been experiencing meaningful insider buying recently are listed below. Here’s what you need to know:

Harvey Norman Holdings Limited (ASX: HVN)

For a second week in a row Gerry Harvey has been in the market adding to his considerable shareholding. According to his change of director’s interest notice, Mr Harvey added an additional 267,589 shares at a combined price of $974,425.34. This leaves Harvey with a total interest of just under 250 million shares. Despite all his buying, Harvey Norman’s shares are still within a whisker of their 52-week low.

Nufarm Limited (ASX: NUF)

A change of director’s interest notice reveals that director Marie McDonald has acquired 8,584 shares at a price of $8.72 per share through an on-market trade. These are the first shares picked up by McDonald, who is also a director of CSL Limited (ASX: CSL). Last week Nufarm delivered a strong half-year result which was well-received by the market and led to Ord Minnett upgrading its shares to a buy rating.

Polynovo Ltd (ASX: PNV)

According to a change of director’s interest notice, non-executive chairman David Williams has increased his indirect interest in the company through the purchase of 2,100,000 shares at 49 cents per share via an on-market trade. This has increased Mr Williams’ interest in the dermal regeneration-focused medical device company to 14.1 million shares. Last month Polynovo reported a 31% increase in half-year revenue to $2.75 million.

Top 3 Growth Shares To Buy In April

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!